Home » Newsletters » BioWorld Science

BioWorld Science

April 12, 2013

View Archived Issues

Novel LM-Kras vaccine delays progression of pancreatic intraepithelial neoplasia in vivo

Potential new treatment for patients susceptible to lactic acidosis

Novel protein Wnt signaling inhibitors synthesized at Samumed

Development of novel ERK inhibitor SCH-772984 reported

Bayer presents BAY-ACC001 as a potent and selective AAC inhibitor

AstraZeneca reports on novel ATR inhibitor AZD-6738

New protein kinase inhibitors designed by Merck KGaA

Sanofi develops novel DGAT1 inhibitors for metabolic disorders

GR modulators show promise in models of respiratory diseases

Abbott obtains CE mark for galectin-3 heart failure test

Johns Hopkins University patents new chymase inhibitors

Sanofi Pasteur's quadrivalent influenza vaccine accepted for review in Europe

Quest Diagnostics launches new tests for rheumatoid arthritis

VereFlu detects current H7N9 avian flu subtype

Sarepta Therapeutics and UWA expand agreement for exon-skipping program

Lundbeck designs novel mGlu5 receptor allosteric modulators

Avioq launches Avioq HTLV-I/II test in Europe

Photocure reports final results from phase IIb study of Cevira

Gamida Cell reports results from final analyses of phase II/III study of StemEx

Novel NS5B inhibitors disclosed by Biota Scientific Management

Confirmatory phase III study not required for filing pimavanserin NDA

New CDK9/cyclin-T1 inhibitors divulged by Bayer Intellectual Property

Sarah Cannon Research Institute to conduct phase II study of OGX-427

First European launch for Jetrea in U.K.

Aptalis launches Pylera in France

FDA accepts Varisolve NDA for full review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...